GASTRO INTESTINAL AND DIGESTIVE CARE
  • Animeal

GASTRO INTESTINAL AND DIGESTIVE CARE

PETVOMI - FIX 4MG TABLET

PETVOMI - FIX 4MG TABLET

By ORIHEAL

₹ 53.44
₹ 53.44
Tax included. Shipping calculated at checkout.

In Stock

Pack - 10Tabs
Expires on or after: Feb, 2027

Prescription Required question

Title

Check Availability

Rapid 3-4 Day Delivery,Tiny Extra Fee!

  • AnimealPet Safe
  • AnimealBest Quality
  • AnimealFast Delivery
  • AnimealSecure Payment
View full details

Oriheal PetVomi Fix Palatable Ondansetron 4 mg Tablet is a professionally formulated, prescription-strength antiemetic designed for the effective management of nausea and severe vomiting in dogs and cats. Developed by OriHeal Life Sciences Pvt. Ltd. a dedicated Indian veterinary pharmaceutical company headquartered in New Delhi PetVomi Fix brings the proven anti-nausea efficacy of Ondansetron Hydrochloride IP to a palatable, chicken-flavoured oral tablet format that greatly facilitates administration in companion animal patients. Ondansetron is a selective 5-HT₃ (serotonin type 3) receptor antagonist one of the most targeted and clinically reliable antiemetic mechanisms available in both human and veterinary pharmacology. It works at two critical anatomical sites: the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) of the brain, interrupting the serotonergic signals that trigger the vomiting reflex. The 4 mg tablet strength is specifically suited for small-to-medium weight patients enabling precise weight-based dosing without the need for tablet splitting across a wide range of body sizes. PetVomi Fix is indicated for severe emesis of multiple aetiologies, including chemotherapy-associated vomiting, parvoviral enteritis, vestibular disease, pancreatitis, chronic kidney disease (CKD)-associated nausea in cats, and pre/post-anaesthetic nausea management. With Oriheal PetVomi Fix, you can trust that you are offering your animal patient the very best in targeted antiemetic pharmaceutical care

Ingredients:

Ondansetron Hydrochloride IP (as Ondansetron 4 mg):Ondansetron is a highly selective, competitive antagonist of serotonin (5-hydroxytryptamine; 5-HT) at the 5-HT₃ receptor subtype. Its antiemetic action is mediated through two distinct but complementary anatomical pathways

Chicken Flavour Base (Excipient): The palatable chicken-flavoured tablet base is a key formulation advantage of PetVomi Fix. The flavour mask significantly reduces resistance and stress during oral administration in cats and small dogs species that are notoriously difficult to medicate improving owner compliance and ensuring consistent therapeutic dosing in clinical and home settings.

Dual-Site 5-HT₃ Blockade The Most Targeted Antiemetic Mechanism:
Ondansetron's mechanism of action is among the most pharmacologically specific of all antiemetic drugs used in veterinary medicine. By selectively targeting the 5-HT₃ receptor rather than broadly antagonising multiple receptor types it achieves powerful anti-nausea and anti-vomiting effects with a markedly cleaner side effect profile than older antiemetics such as metoclopramide (dopamine antagonist) or chlorpromazine (phenothiazine). Veterinarians can use PetVomi Fix with confidence in patients where a targeted, receptor-specific antiemetic intervention is required, particularly when the emetic stimulus is primarily serotonergic in origin as is the case with most chemotherapy protocols and many gastrointestinal infections.

4 mg Strength Precision Dosing for Small-to-Medium Patients:
The 4 mg tablet strength of PetVomi Fix is deliberately designed for precise weight-based dosing in small-to-medium companion animals cats, small-breed dogs, and medium-breed dogs without the need for tablet halving or quartering that can compromise accurate dosing. Given that ondansetron is dosed by body weight (mg/kg), having an appropriate lower-strength tablet directly available ensures dosing accuracy and reduces the risk of under- or over-dosing in this size category. The 4 mg strength complements the 8 mg variant also available in the PetVomi Fix range, giving veterinarians dosing flexibility across a wide range of patient weights.

Palatable Chicken-Flavoured Tablet for Superior Compliance:
One of the most clinically significant challenges in companion animal pharmacotherapy particularly in cats is the refusal or active avoidance of oral medications. Cats are particularly medication-averse, and standard uncoated pharmaceutical tablets often require pilling aids, food hiding, or restraint techniques that cause animal distress and reduce client compliance with dosing schedules. PetVomi Fix's palatable chicken-flavoured tablet base directly addresses this challenge, significantly improving the ease and reliability of oral medication delivery. Improved palatability translates to improved dosing consistency, which translates directly to better therapeutic outcomes a benefit of practical importance in conditions requiring multi-day antiemetic courses.

Validated for Chemotherapy-Induced Emesis Drug of Choice:
Chemotherapy-associated nausea and vomiting (CINV) remains one of the most challenging clinical management problems in veterinary oncology. Serotonin release from enterochromaffin cells in the GI tract is a primary mediator of CINV, making 5-HT₃ receptor antagonists the mechanistically optimal pharmacological intervention. Ondansetron is well-established in the veterinary oncology literature as an effective and well-tolerated antiemetic for dogs and cats undergoing cytotoxic chemotherapy. PetVomi Fix Ondansetron 4 mg provides veterinary oncologists and general practitioners managing oncology patients with a reliably formulated, India-manufactured, cost-effective option for this demanding clinical application.

Broad Indication Profile Multiple Emetic Aetiologies:
PetVomi Fix is clinically indicated across a wide range of emetic presentations in both dogs and cats: severe acute vomiting from GI infections including parvoviral enteritis; vestibular disease-associated nausea; pancreatitis; chronic kidney disease (CKD)-associated nausea and vomiting in cats; perioperative (pre- and post-anaesthetic) nausea management; motion sickness in select cases; opioid-related pruritus (secondary to spinal or epidural opioid administration); and sleep apnoea management in brachycephalic breeds (e.g., Bulldogs). This breadth of application makes PetVomi Fix a versatile addition to any veterinary formulary or clinic's prescription antiemetic inventory.

Indian GMP Manufacture OriHeal Life Sciences
PetVomi Fix is manufactured by OriHeal Life Sciences Pvt. Ltd. an Indian veterinary pharmaceutical company ensuring that procurement, supply chain management, and regulatory compliance are aligned with Indian veterinary pharmaceutical standards. Domestic Indian manufacturing affords advantages in stock availability, pricing accessibility, and supply chain reliability compared to imported equivalents, making PetVomi Fix a pragmatic choice for Indian veterinary clinics and procurement officers managing formulary costs without compromising on pharmacological quality.

Rapid Onset Clinical Effect Within 1–2 Hours:
Oral ondansetron achieves measurable plasma concentrations within the therapeutic range within approximately 1–2 hours of administration in dogs and cats, providing timely relief from active nausea and vomiting in the clinical setting. This relatively rapid onset of action is particularly valuable in acute emetic presentations such as post-surgical recovery, active chemotherapy sessions, or acute GI infections where prompt emesis control improves patient comfort, reduces the risk of dehydration and electrolyte imbalance, and facilitates earlier return to voluntary food and water intake.

How to Use:

Administer the tablet orally, directly or concealed in a small amount of palatable food or a pill pocket to facilitate acceptance.

May be administered with or without food. If vomiting occurs when given on an empty stomach, administer with a small food offering at subsequent doses.

Ensure the patient swallows the tablet completely particularly important in cats who may hold the tablet before expectorating.

For pre-chemotherapy use, administer orally 30 minutes before cytotoxic agent administration; may be repeated every 8–12 hours as directed.

Fresh water should always be available during the treatment course.

Storage Instructions:

Store PetVomi Fix Ondansetron 4 mg Tablets in a cool, dry place between 2°C and 30°C (36°F–86°F), away from direct sunlight, heat, and moisture. Store in the original, tight, light-resistant packaging until point of use. Keep out of reach of children and non-target animals. Do not use beyond the printed expiry date. Tablets that appear discoloured, crumbled, or whose packaging has been compromised should not be dispensed.

About the Brand:

OriHeal Life Sciences Pvt. Ltd. is an Indian veterinary pharmaceutical company headquartered in New Delhi, dedicated to developing and manufacturing a comprehensive range of veterinary medicines spanning gastro-intestinal, ophthalmic, cardiac, and general medicine categories for companion and large animals. OriHeal's PetVomi Fix range available in both tablet and oral suspension formulations reflects the brand's commitment to making clinically important veterinary pharmaceuticals accessible to Indian veterinary professionals in well-formulated, palatable, and cost-effective presentations. OriHeal Life Sciences' commitment to quality veterinary pharmaceutical manufacturing and clinical relevance aligns perfectly with Animeal's mission to bring only the very best in veterinary pharmaceutical procurement to licensed veterinary professionals and registered clinics across India.

Disclaimer:

Ondansetron is an extra-label/off-label drug in veterinary medicine. Dosing, frequency, and duration of treatment must be individualised by a licensed veterinarian based on the patient's body weight, clinical diagnosis, organ function (particularly hepatic status), concurrent medications, and breed-specific genetic factors (MDR1 mutation). Serious adverse effects — though rare — may include constipation, mild sedation, extrapyramidal signs (head shaking), cardiac arrhythmias (QT prolongation), serotonin syndrome (when used concurrently with other serotonergic agents), and hypotension. Overdose in animals has been associated with sudden, transient loss of vision, severe constipation, and hypotension. If any adverse signs develop following administration, discontinue the medication and contact the attending veterinarian immediately. This product should not be used in pregnant or lactating animals without specific veterinary assessment of risk and benefit. Do not use in animals with known gastrointestinal obstruction or hypersensitivity to ondansetron.

Q: What is Oriheal PetVomi Fix Ondansetron 4 mg Tablet indicated for in dogs and cats?
Oriheal PetVomi Fix Palatable Ondansetron 4 mg Tablet is indicated for the management of severe nausea and vomiting in dogs and cats across a range of clinical aetiologies. Its primary indications include chemotherapy-induced nausea and vomiting (CINV) where it is considered a drug of choice due to the serotonergic mechanism of chemotherapy-associated emesis as well as severe acute vomiting from parvoviral enteritis, vestibular disease, pancreatitis, toxin ingestion, and post-anaesthetic nausea. In cats specifically, PetVomi Fix is used for chronic kidney disease (CKD)-associated nausea, a highly prevalent quality-of-life concern in geriatric feline patients. Secondary indications include the management of opioid-induced pruritus (itching secondary to spinal or epidural opioid administration) and sleep apnoea management in brachycephalic dog breeds such as Bulldogs. The breadth of this indication profile makes PetVomi Fix a versatile and valuable antiemetic in any veterinary clinic's formulary, covering both acute episodic vomiting and chronic nausea management scenarios.
Q: How does Ondansetron's mechanism of action compare to other antiemetics used in veterinary medicine?
Ondansetron distinguishes itself pharmacologically from other commonly used veterinary antiemetics through its receptor specificity. Metoclopramide arguably the most widely used antiemetic in Indian veterinary practice works primarily as a dopamine (D₂) receptor antagonist in the CTZ, with additional prokinetic effects via GI tract dopamine blockade. However, metoclopramide's dopaminergic blockade also produces extrapyramidal side effects (tremors, restlessness, abnormal movements) in some patients, limits its use in GI motility disorders, and offers comparatively weaker efficacy in chemotherapy-induced emesis where serotonin (not dopamine) is the dominant emetogens. Maropitant (Cerenia®) the other widely referenced veterinary antiemetic works via NK₁ (neurokinin-1) receptor antagonism and is FDA-approved for veterinary use. While maropitant is highly effective and broadly indicated, ondansetron may be superior or complementary in scenarios where serotonergic mechanisms predominate. PetVomi Fix Ondansetron can be used as a sole antiemetic or in combination protocols with maropitant in refractory or complex vomiting cases, as the two drugs act at distinct receptor sites and are pharmacologically compatible though all combination protocols should be supervised by a veterinarian.
Q: What are the expected clinical outcomes and timeline of response with PetVomi Fix Ondansetron 4 mg?
Following oral administration, ondansetron is absorbed and reaches pharmacologically active plasma concentrations within approximately 1–2 hours. In dogs with acute emesis, clinical reduction in vomiting frequency is typically observed within 2–4 hours of the first dose. In cats, oral bioavailability of ondansetron has been documented at approximately 32% lower than in humans (62%) but meaningfully higher than in rats and dogs (less than 10%), where extensive first-pass hepatic metabolism significantly limits oral bioavailability. This pharmacokinetic difference in cats supports the appropriateness of oral ondansetron use in feline patients, though veterinarians should be aware that more frequent dosing (every 8 hours) may be required in cats to maintain therapeutic plasma concentrations through the dosing interval, as supported by published pharmacokinetic studies. For chemotherapy patients, the antiemetic effect is most reliable when the first dose is administered 30 minutes prior to cytotoxic drug administration, with subsequent doses at 8–12 hour intervals for 24–48 hours post-chemotherapy. Veterinarians should reassess response at 24–48 hours and adjust the dosing protocol accordingly.
Q: What are the contraindications, potential side effects, and important drug interactions that prescribing veterinarians should be aware of?
PetVomi Fix Ondansetron 4 mg is generally well tolerated in both dogs and cats at therapeutic doses, with a favourable safety margin. However, prescribing veterinarians must be aware of the following important clinical considerations. Absolute contraindications include known hypersensitivity to ondansetron and the presence of gastrointestinal obstruction (ondansetron's reduction of GI motility can worsen obstructive conditions). Caution is warranted in patients with hepatic disease reduced first-pass metabolism increases systemic drug exposure and prolongs half-life, potentially necessitating dose reduction. MDR1 (ABCB1)-positive dog breeds including Collies, Shetland Sheepdogs, Australian Shepherds, and their crossbreeds may exhibit altered drug handling due to P-glycoprotein efflux pump dysfunction, and should be treated with additional care and monitoring. Drug interactions of clinical significance include reduced efficacy of tramadol (ondansetron may antagonise the analgesic effect by blocking spinal serotonin receptors involved in tramadol's action concurrent analgesic regimens may need adjustment), risk of serotonin syndrome when combined with other serotonergic agents (e.g., mirtazapine, tramadol at high doses, TCAs, MAOIs), and potential QT interval prolongation when used alongside other QT-prolonging medications. Rare but serious adverse effects in animals may include constipation, mild sedation, extrapyramidal signs, and at overdose levels sudden transient vision loss, severe constipation, and hypotension. Cardiac monitoring is advisable in patients with pre-existing cardiac conduction abnormalities receiving ondansetron.
Q: How can veterinary professionals procure Oriheal PetVomi Fix Ondansetron 4 mg Tablets through Animeal?
Registered veterinary professionals and licensed veterinary pharmacies can enquire about and procure Oriheal PetVomi Fix Palatable Ondansetron 4 mg Tablets through Animeal's dedicated veterinary pharmaceutical enquiry channel. To initiate procurement, please use the Enquire Now button on this product listing page, or reach out to the Animeal team directly via WhatsApp or phone with your prescription details, veterinary registration number, and institutional or clinic information. Animeal facilitates transparent, compliant procurement of Schedule H veterinary pharmaceuticals for licensed professionals only ensuring that every order is processed in accordance with Indian veterinary drug regulatory requirements. Our team is equipped to assist with bulk clinic orders, repeat prescription procurement, and formulary supply queries. All enquiries are handled with professionalism and discretion.
PETVOMI - FIX 4MG TABLET - Animeal
GASTRO INTESTINAL AND DIGESTIVE CARE
🚚 FREE delivery on orders above ₹499
10 DaysEasy Returns
100%Authentic
SecurePayments
GASTRO INTESTINAL AND DIGESTIVE CARE

PETVOMI - FIX 4MG TABLET

By ORIHEAL
₹ 48.09
You save ₹ 5.35 (10%)
MRP ₹ 53.44 (Incl. taxes)

In Stock

Size

Prescription Required question

₹ 48.09
MRP ₹ 53.44  10% OFF
1
Check Availability

Oriheal PetVomi Fix Palatable Ondansetron 4 mg Tablet is a professionally formulated, prescription-strength antiemetic designed for the effective management of nausea and severe vomiting in dogs and cats. Developed by OriHeal Life Sciences Pvt. Ltd. a dedicated Indian veterinary pharmaceutical company headquartered in New Delhi PetVomi Fix brings the proven anti-nausea efficacy of Ondansetron Hydrochloride IP to a palatable, chicken-flavoured oral tablet format that greatly facilitates administration in companion animal patients. Ondansetron is a selective 5-HT₃ (serotonin type 3) receptor antagonist one of the most targeted and clinically reliable antiemetic mechanisms available in both human and veterinary pharmacology. It works at two critical anatomical sites: the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) of the brain, interrupting the serotonergic signals that trigger the vomiting reflex. The 4 mg tablet strength is specifically suited for small-to-medium weight patients enabling precise weight-based dosing without the need for tablet splitting across a wide range of body sizes. PetVomi Fix is indicated for severe emesis of multiple aetiologies, including chemotherapy-associated vomiting, parvoviral enteritis, vestibular disease, pancreatitis, chronic kidney disease (CKD)-associated nausea in cats, and pre/post-anaesthetic nausea management. With Oriheal PetVomi Fix, you can trust that you are offering your animal patient the very best in targeted antiemetic pharmaceutical care

Ingredients:

Ondansetron Hydrochloride IP (as Ondansetron 4 mg):Ondansetron is a highly selective, competitive antagonist of serotonin (5-hydroxytryptamine; 5-HT) at the 5-HT₃ receptor subtype. Its antiemetic action is mediated through two distinct but complementary anatomical pathways

Chicken Flavour Base (Excipient): The palatable chicken-flavoured tablet base is a key formulation advantage of PetVomi Fix. The flavour mask significantly reduces resistance and stress during oral administration in cats and small dogs species that are notoriously difficult to medicate improving owner compliance and ensuring consistent therapeutic dosing in clinical and home settings.

Dual-Site 5-HT₃ Blockade The Most Targeted Antiemetic Mechanism:
Ondansetron's mechanism of action is among the most pharmacologically specific of all antiemetic drugs used in veterinary medicine. By selectively targeting the 5-HT₃ receptor rather than broadly antagonising multiple receptor types it achieves powerful anti-nausea and anti-vomiting effects with a markedly cleaner side effect profile than older antiemetics such as metoclopramide (dopamine antagonist) or chlorpromazine (phenothiazine). Veterinarians can use PetVomi Fix with confidence in patients where a targeted, receptor-specific antiemetic intervention is required, particularly when the emetic stimulus is primarily serotonergic in origin as is the case with most chemotherapy protocols and many gastrointestinal infections.

4 mg Strength Precision Dosing for Small-to-Medium Patients:
The 4 mg tablet strength of PetVomi Fix is deliberately designed for precise weight-based dosing in small-to-medium companion animals cats, small-breed dogs, and medium-breed dogs without the need for tablet halving or quartering that can compromise accurate dosing. Given that ondansetron is dosed by body weight (mg/kg), having an appropriate lower-strength tablet directly available ensures dosing accuracy and reduces the risk of under- or over-dosing in this size category. The 4 mg strength complements the 8 mg variant also available in the PetVomi Fix range, giving veterinarians dosing flexibility across a wide range of patient weights.

Palatable Chicken-Flavoured Tablet for Superior Compliance:
One of the most clinically significant challenges in companion animal pharmacotherapy particularly in cats is the refusal or active avoidance of oral medications. Cats are particularly medication-averse, and standard uncoated pharmaceutical tablets often require pilling aids, food hiding, or restraint techniques that cause animal distress and reduce client compliance with dosing schedules. PetVomi Fix's palatable chicken-flavoured tablet base directly addresses this challenge, significantly improving the ease and reliability of oral medication delivery. Improved palatability translates to improved dosing consistency, which translates directly to better therapeutic outcomes a benefit of practical importance in conditions requiring multi-day antiemetic courses.

Validated for Chemotherapy-Induced Emesis Drug of Choice:
Chemotherapy-associated nausea and vomiting (CINV) remains one of the most challenging clinical management problems in veterinary oncology. Serotonin release from enterochromaffin cells in the GI tract is a primary mediator of CINV, making 5-HT₃ receptor antagonists the mechanistically optimal pharmacological intervention. Ondansetron is well-established in the veterinary oncology literature as an effective and well-tolerated antiemetic for dogs and cats undergoing cytotoxic chemotherapy. PetVomi Fix Ondansetron 4 mg provides veterinary oncologists and general practitioners managing oncology patients with a reliably formulated, India-manufactured, cost-effective option for this demanding clinical application.

Broad Indication Profile Multiple Emetic Aetiologies:
PetVomi Fix is clinically indicated across a wide range of emetic presentations in both dogs and cats: severe acute vomiting from GI infections including parvoviral enteritis; vestibular disease-associated nausea; pancreatitis; chronic kidney disease (CKD)-associated nausea and vomiting in cats; perioperative (pre- and post-anaesthetic) nausea management; motion sickness in select cases; opioid-related pruritus (secondary to spinal or epidural opioid administration); and sleep apnoea management in brachycephalic breeds (e.g., Bulldogs). This breadth of application makes PetVomi Fix a versatile addition to any veterinary formulary or clinic's prescription antiemetic inventory.

Indian GMP Manufacture OriHeal Life Sciences
PetVomi Fix is manufactured by OriHeal Life Sciences Pvt. Ltd. an Indian veterinary pharmaceutical company ensuring that procurement, supply chain management, and regulatory compliance are aligned with Indian veterinary pharmaceutical standards. Domestic Indian manufacturing affords advantages in stock availability, pricing accessibility, and supply chain reliability compared to imported equivalents, making PetVomi Fix a pragmatic choice for Indian veterinary clinics and procurement officers managing formulary costs without compromising on pharmacological quality.

Rapid Onset Clinical Effect Within 1–2 Hours:
Oral ondansetron achieves measurable plasma concentrations within the therapeutic range within approximately 1–2 hours of administration in dogs and cats, providing timely relief from active nausea and vomiting in the clinical setting. This relatively rapid onset of action is particularly valuable in acute emetic presentations such as post-surgical recovery, active chemotherapy sessions, or acute GI infections where prompt emesis control improves patient comfort, reduces the risk of dehydration and electrolyte imbalance, and facilitates earlier return to voluntary food and water intake.

How to Use:

Administer the tablet orally, directly or concealed in a small amount of palatable food or a pill pocket to facilitate acceptance.

May be administered with or without food. If vomiting occurs when given on an empty stomach, administer with a small food offering at subsequent doses.

Ensure the patient swallows the tablet completely particularly important in cats who may hold the tablet before expectorating.

For pre-chemotherapy use, administer orally 30 minutes before cytotoxic agent administration; may be repeated every 8–12 hours as directed.

Fresh water should always be available during the treatment course.

Storage Instructions:

Store PetVomi Fix Ondansetron 4 mg Tablets in a cool, dry place between 2°C and 30°C (36°F–86°F), away from direct sunlight, heat, and moisture. Store in the original, tight, light-resistant packaging until point of use. Keep out of reach of children and non-target animals. Do not use beyond the printed expiry date. Tablets that appear discoloured, crumbled, or whose packaging has been compromised should not be dispensed.

About the Brand:

OriHeal Life Sciences Pvt. Ltd. is an Indian veterinary pharmaceutical company headquartered in New Delhi, dedicated to developing and manufacturing a comprehensive range of veterinary medicines spanning gastro-intestinal, ophthalmic, cardiac, and general medicine categories for companion and large animals. OriHeal's PetVomi Fix range available in both tablet and oral suspension formulations reflects the brand's commitment to making clinically important veterinary pharmaceuticals accessible to Indian veterinary professionals in well-formulated, palatable, and cost-effective presentations. OriHeal Life Sciences' commitment to quality veterinary pharmaceutical manufacturing and clinical relevance aligns perfectly with Animeal's mission to bring only the very best in veterinary pharmaceutical procurement to licensed veterinary professionals and registered clinics across India.

Disclaimer:

Ondansetron is an extra-label/off-label drug in veterinary medicine. Dosing, frequency, and duration of treatment must be individualised by a licensed veterinarian based on the patient's body weight, clinical diagnosis, organ function (particularly hepatic status), concurrent medications, and breed-specific genetic factors (MDR1 mutation). Serious adverse effects — though rare — may include constipation, mild sedation, extrapyramidal signs (head shaking), cardiac arrhythmias (QT prolongation), serotonin syndrome (when used concurrently with other serotonergic agents), and hypotension. Overdose in animals has been associated with sudden, transient loss of vision, severe constipation, and hypotension. If any adverse signs develop following administration, discontinue the medication and contact the attending veterinarian immediately. This product should not be used in pregnant or lactating animals without specific veterinary assessment of risk and benefit. Do not use in animals with known gastrointestinal obstruction or hypersensitivity to ondansetron.

Q: What is Oriheal PetVomi Fix Ondansetron 4 mg Tablet indicated for in dogs and cats?
Oriheal PetVomi Fix Palatable Ondansetron 4 mg Tablet is indicated for the management of severe nausea and vomiting in dogs and cats across a range of clinical aetiologies. Its primary indications include chemotherapy-induced nausea and vomiting (CINV) where it is considered a drug of choice due to the serotonergic mechanism of chemotherapy-associated emesis as well as severe acute vomiting from parvoviral enteritis, vestibular disease, pancreatitis, toxin ingestion, and post-anaesthetic nausea. In cats specifically, PetVomi Fix is used for chronic kidney disease (CKD)-associated nausea, a highly prevalent quality-of-life concern in geriatric feline patients. Secondary indications include the management of opioid-induced pruritus (itching secondary to spinal or epidural opioid administration) and sleep apnoea management in brachycephalic dog breeds such as Bulldogs. The breadth of this indication profile makes PetVomi Fix a versatile and valuable antiemetic in any veterinary clinic's formulary, covering both acute episodic vomiting and chronic nausea management scenarios.
Q: How does Ondansetron's mechanism of action compare to other antiemetics used in veterinary medicine?
Ondansetron distinguishes itself pharmacologically from other commonly used veterinary antiemetics through its receptor specificity. Metoclopramide arguably the most widely used antiemetic in Indian veterinary practice works primarily as a dopamine (D₂) receptor antagonist in the CTZ, with additional prokinetic effects via GI tract dopamine blockade. However, metoclopramide's dopaminergic blockade also produces extrapyramidal side effects (tremors, restlessness, abnormal movements) in some patients, limits its use in GI motility disorders, and offers comparatively weaker efficacy in chemotherapy-induced emesis where serotonin (not dopamine) is the dominant emetogens. Maropitant (Cerenia®) the other widely referenced veterinary antiemetic works via NK₁ (neurokinin-1) receptor antagonism and is FDA-approved for veterinary use. While maropitant is highly effective and broadly indicated, ondansetron may be superior or complementary in scenarios where serotonergic mechanisms predominate. PetVomi Fix Ondansetron can be used as a sole antiemetic or in combination protocols with maropitant in refractory or complex vomiting cases, as the two drugs act at distinct receptor sites and are pharmacologically compatible though all combination protocols should be supervised by a veterinarian.
Q: What are the expected clinical outcomes and timeline of response with PetVomi Fix Ondansetron 4 mg?
Following oral administration, ondansetron is absorbed and reaches pharmacologically active plasma concentrations within approximately 1–2 hours. In dogs with acute emesis, clinical reduction in vomiting frequency is typically observed within 2–4 hours of the first dose. In cats, oral bioavailability of ondansetron has been documented at approximately 32% lower than in humans (62%) but meaningfully higher than in rats and dogs (less than 10%), where extensive first-pass hepatic metabolism significantly limits oral bioavailability. This pharmacokinetic difference in cats supports the appropriateness of oral ondansetron use in feline patients, though veterinarians should be aware that more frequent dosing (every 8 hours) may be required in cats to maintain therapeutic plasma concentrations through the dosing interval, as supported by published pharmacokinetic studies. For chemotherapy patients, the antiemetic effect is most reliable when the first dose is administered 30 minutes prior to cytotoxic drug administration, with subsequent doses at 8–12 hour intervals for 24–48 hours post-chemotherapy. Veterinarians should reassess response at 24–48 hours and adjust the dosing protocol accordingly.
Q: What are the contraindications, potential side effects, and important drug interactions that prescribing veterinarians should be aware of?
PetVomi Fix Ondansetron 4 mg is generally well tolerated in both dogs and cats at therapeutic doses, with a favourable safety margin. However, prescribing veterinarians must be aware of the following important clinical considerations. Absolute contraindications include known hypersensitivity to ondansetron and the presence of gastrointestinal obstruction (ondansetron's reduction of GI motility can worsen obstructive conditions). Caution is warranted in patients with hepatic disease reduced first-pass metabolism increases systemic drug exposure and prolongs half-life, potentially necessitating dose reduction. MDR1 (ABCB1)-positive dog breeds including Collies, Shetland Sheepdogs, Australian Shepherds, and their crossbreeds may exhibit altered drug handling due to P-glycoprotein efflux pump dysfunction, and should be treated with additional care and monitoring. Drug interactions of clinical significance include reduced efficacy of tramadol (ondansetron may antagonise the analgesic effect by blocking spinal serotonin receptors involved in tramadol's action concurrent analgesic regimens may need adjustment), risk of serotonin syndrome when combined with other serotonergic agents (e.g., mirtazapine, tramadol at high doses, TCAs, MAOIs), and potential QT interval prolongation when used alongside other QT-prolonging medications. Rare but serious adverse effects in animals may include constipation, mild sedation, extrapyramidal signs, and at overdose levels sudden transient vision loss, severe constipation, and hypotension. Cardiac monitoring is advisable in patients with pre-existing cardiac conduction abnormalities receiving ondansetron.
Q: How can veterinary professionals procure Oriheal PetVomi Fix Ondansetron 4 mg Tablets through Animeal?
Registered veterinary professionals and licensed veterinary pharmacies can enquire about and procure Oriheal PetVomi Fix Palatable Ondansetron 4 mg Tablets through Animeal's dedicated veterinary pharmaceutical enquiry channel. To initiate procurement, please use the Enquire Now button on this product listing page, or reach out to the Animeal team directly via WhatsApp or phone with your prescription details, veterinary registration number, and institutional or clinic information. Animeal facilitates transparent, compliant procurement of Schedule H veterinary pharmaceuticals for licensed professionals only ensuring that every order is processed in accordance with Indian veterinary drug regulatory requirements. Our team is equipped to assist with bulk clinic orders, repeat prescription procurement, and formulary supply queries. All enquiries are handled with professionalism and discretion.
PETVOMI - FIX 4MG TABLET
₹ 48.09
₹ 53.44  10% OFF

Frequently Asked Questions

What is Oriheal PetVomi Fix Ondansetron 4 mg Tablet indicated for in dogs and cats?

Oriheal PetVomi Fix Palatable Ondansetron 4 mg Tablet is indicated for the management of severe nausea and vomiting in dogs and cats across a range of clinical aetiologies. Its primary indications include chemotherapy-induced nausea and vomiting (CINV) where it is considered a drug of choice due to the serotonergic mechanism of chemotherapy-associated emesis as well as severe acute vomiting from parvoviral enteritis, vestibular disease, pancreatitis, toxin ingestion, and post-anaesthetic nausea. In cats specifically, PetVomi Fix is used for chronic kidney disease (CKD)-associated nausea, a highly prevalent quality-of-life concern in geriatric feline patients. Secondary indications include the management of opioid-induced pruritus (itching secondary to spinal or epidural opioid administration) and sleep apnoea management in brachycephalic dog breeds such as Bulldogs. The breadth of this indication profile makes PetVomi Fix a versatile and valuable antiemetic in any veterinary clinic's formulary, covering both acute episodic vomiting and chronic nausea management scenarios.

How does Ondansetron's mechanism of action compare to other antiemetics used in veterinary medicine?

Ondansetron distinguishes itself pharmacologically from other commonly used veterinary antiemetics through its receptor specificity. Metoclopramide arguably the most widely used antiemetic in Indian veterinary practice works primarily as a dopamine (D₂) receptor antagonist in the CTZ, with additional prokinetic effects via GI tract dopamine blockade. However, metoclopramide's dopaminergic blockade also produces extrapyramidal side effects (tremors, restlessness, abnormal movements) in some patients, limits its use in GI motility disorders, and offers comparatively weaker efficacy in chemotherapy-induced emesis where serotonin (not dopamine) is the dominant emetogens. Maropitant (Cerenia®) the other widely referenced veterinary antiemetic works via NK₁ (neurokinin-1) receptor antagonism and is FDA-approved for veterinary use. While maropitant is highly effective and broadly indicated, ondansetron may be superior or complementary in scenarios where serotonergic mechanisms predominate. PetVomi Fix Ondansetron can be used as a sole antiemetic or in combination protocols with maropitant in refractory or complex vomiting cases, as the two drugs act at distinct receptor sites and are pharmacologically compatible though all combination protocols should be supervised by a veterinarian.

What are the expected clinical outcomes and timeline of response with PetVomi Fix Ondansetron 4 mg?

Following oral administration, ondansetron is absorbed and reaches pharmacologically active plasma concentrations within approximately 1–2 hours. In dogs with acute emesis, clinical reduction in vomiting frequency is typically observed within 2–4 hours of the first dose. In cats, oral bioavailability of ondansetron has been documented at approximately 32% lower than in humans (62%) but meaningfully higher than in rats and dogs (less than 10%), where extensive first-pass hepatic metabolism significantly limits oral bioavailability. This pharmacokinetic difference in cats supports the appropriateness of oral ondansetron use in feline patients, though veterinarians should be aware that more frequent dosing (every 8 hours) may be required in cats to maintain therapeutic plasma concentrations through the dosing interval, as supported by published pharmacokinetic studies. For chemotherapy patients, the antiemetic effect is most reliable when the first dose is administered 30 minutes prior to cytotoxic drug administration, with subsequent doses at 8–12 hour intervals for 24–48 hours post-chemotherapy. Veterinarians should reassess response at 24–48 hours and adjust the dosing protocol accordingly.

What are the contraindications, potential side effects, and important drug interactions that prescribing veterinarians should be aware of?

PetVomi Fix Ondansetron 4 mg is generally well tolerated in both dogs and cats at therapeutic doses, with a favourable safety margin. However, prescribing veterinarians must be aware of the following important clinical considerations. Absolute contraindications include known hypersensitivity to ondansetron and the presence of gastrointestinal obstruction (ondansetron's reduction of GI motility can worsen obstructive conditions). Caution is warranted in patients with hepatic disease reduced first-pass metabolism increases systemic drug exposure and prolongs half-life, potentially necessitating dose reduction. MDR1 (ABCB1)-positive dog breeds including Collies, Shetland Sheepdogs, Australian Shepherds, and their crossbreeds may exhibit altered drug handling due to P-glycoprotein efflux pump dysfunction, and should be treated with additional care and monitoring. Drug interactions of clinical significance include reduced efficacy of tramadol (ondansetron may antagonise the analgesic effect by blocking spinal serotonin receptors involved in tramadol's action concurrent analgesic regimens may need adjustment), risk of serotonin syndrome when combined with other serotonergic agents (e.g., mirtazapine, tramadol at high doses, TCAs, MAOIs), and potential QT interval prolongation when used alongside other QT-prolonging medications. Rare but serious adverse effects in animals may include constipation, mild sedation, extrapyramidal signs, and at overdose levels sudden transient vision loss, severe constipation, and hypotension. Cardiac monitoring is advisable in patients with pre-existing cardiac conduction abnormalities receiving ondansetron.

How can veterinary professionals procure Oriheal PetVomi Fix Ondansetron 4 mg Tablets through Animeal?

Registered veterinary professionals and licensed veterinary pharmacies can enquire about and procure Oriheal PetVomi Fix Palatable Ondansetron 4 mg Tablets through Animeal's dedicated veterinary pharmaceutical enquiry channel. To initiate procurement, please use the Enquire Now button on this product listing page, or reach out to the Animeal team directly via WhatsApp or phone with your prescription details, veterinary registration number, and institutional or clinic information. Animeal facilitates transparent, compliant procurement of Schedule H veterinary pharmaceuticals for licensed professionals only ensuring that every order is processed in accordance with Indian veterinary drug regulatory requirements. Our team is equipped to assist with bulk clinic orders, repeat prescription procurement, and formulary supply queries. All enquiries are handled with professionalism and discretion.
View All Questions